Does EBV early-antigen IgG prove active Epstein-Barr virus replication?

EBV early-antigen (EA) IgG is best viewed as a contextual marker of immune exposure to lytic EBV proteins, not a direct measurement of current viral replication. This distinction is particularly important when interpreting an isolated positive result in an older adult without a compatible acute clinical syndrome.

Clinical interpretation

• EA IgG may be detectable during acute EBV infection or reactivation, but it is temporally indirect. A positive result can support consideration of recent viral activity; it cannot establish that replication is occurring at the time of testing.
• Persistence is common enough to limit specificity: EA-D IgG often declines within 3–6 months after acute illness, yet remains detectable for years in approximately 20–30% of previously infected healthy people.
• A past-infection profile—typically VCA IgG positive, EBNA IgG positive, and VCA IgM negative—may coexist with persistent EA IgG and does not demonstrate reactivation.

Mechanistic context

• EBV reactivation activates the viral lytic gene cascade: immediate-early viral proteins induce early lytic genes, producing antigens that can elicit EA-directed IgG.
• This mechanism explains why EA IgG can accompany reactivation, but antibody persistence after the lytic episode explains why seropositivity is not equivalent to active replication.

Practical implications

• Serologic and molecular results may disagree. In one report, EBV DNA was found in only 2 of 62 samples categorized as serologic reactivation; in immunosuppressed populations, reactivation-associated serology also did not reliably correlate with EBV DNA in peripheral leukocytes.
• Interpretation should integrate symptoms, VCA/EBNA serology, immune status, and—when clinically indicated—quantitative EBV PCR. PCR also requires caution because blood EBV DNA can reflect latent infected cells and depends on specimen type.

Bottom line

• EA IgG can occur with EBV reactivation, but persistent positivity after remote infection is well documented; therefore, EA IgG alone is not definitive evidence of active EBV replication.